{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T15:06:53Z","timestamp":1789657613454,"version":"4.0.1"},"reference-count":12,"publisher":"MJS Publishing, Medical Journals Sweden AB","license":[{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Derm Venereol"],"DOI":"10.2340\/actadv.v106.adv-2026-0559","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T14:19:03Z","timestamp":1789654743000},"source":"Crossref","is-referenced-by-count":0,"title":["Anifrolumab in Refractory Discoid Lupus Erythematosus without Systemic Involvement: A Case Series of Five Patients"],"prefix":"10.2340","volume":"106","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-9178-873X","authenticated-orcid":false,"given":"Jasmin","family":"Marschner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5147-0123","authenticated-orcid":false,"given":"Franziska","family":"Schauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1183","published-online":{"date-parts":[[2026,9,17]]},"reference":[{"key":"168635","doi-asserted-by":"crossref","unstructured":"Xie L, Lopes Almeida Gomes L, Stone CJ, Faden DF, Werth VP. An update on clinical trials for cutaneous lupus erythematosus. J Dermatol 2024; 51: 885\u2013894.","DOI":"10.1111\/1346-8138.17161"},{"key":"168636","unstructured":"Deutsche Gesellschaft f\u00fcr Rheumatologie e.V., Deutsche Dermatologische Gesellschaft e.V., Gesellschaft f\u00fcr P\u00e4diatrische Dermatologie. Diagnostik und Therapie des kutanen Lupus erythematodes (S2k-Leitlinie); 2020. [cited 2025 April 28]. Available from: https:\/\/www.awmf.org\/uploads\/tx_szleitlinien\/013-060l_S2k_Kutaner_Lupus_erythematodes_2020-06-verlaengert.pdf."},{"key":"168637","doi-asserted-by":"crossref","unstructured":"Furie R, Khamashta M, Merrill JT, Werth VP, Kalunian K, Brohawn P, et al. Anifrolumab, an anti\u2013interferon\u2010\u03b1 receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus. Arthritis Rheumatol 2017; 69: 376\u2013386.","DOI":"10.1002\/art.39962"},{"key":"168638","doi-asserted-by":"crossref","unstructured":"Furie RA, Morand EF, Bruce IN, Manzi S, Kalunian KC, Vital EM, et al. Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial. Lancet Rheumatol 2019; 1: e208\u2013e219.","DOI":"10.1016\/S2665-9913(19)30076-1"},{"key":"168639","doi-asserted-by":"crossref","unstructured":"Pl\u00fc\u00df M, Piantoni S, Wincup C, Korsten P. Rapid response of refractory systemic lupus erythematosus skin manifestations to anifrolumab\u2014a case-based review of clinical trial data suggesting a domain-based therapeutic approach. J Clin Med 2022; 11: 3449.","DOI":"10.3390\/jcm11123449"},{"key":"168640","doi-asserted-by":"crossref","unstructured":"Morand EF, Furie RA, Bruce IN, Vital EM, Dall\u2019Era M, Maho E, et al. Efficacy of anifrolumab across organ domains in patients with moderate-to-severe systemic lupus erythematosus: a post-hoc analysis of pooled data from the TULIP-1 and TULIP-2 trials. Lancet Rheumatol 2022; 4: e282\u2013e292.","DOI":"10.1016\/S2665-9913(21)00317-9"},{"key":"168641","doi-asserted-by":"crossref","unstructured":"Baechler EC, Batliwalla FM, Karypis G, Gaffney PM, Ortmann WA, Espe KJ, et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci USA 2003; 100: 2610\u20132615.","DOI":"10.1073\/pnas.0337679100"},{"key":"168642","doi-asserted-by":"crossref","unstructured":"Braunstein I, Klein R, Okawa J, Werth VP. The interferon-regulated gene signature is elevated in subacute cutaneous lupus erythematosus and discoid lupus erythematosus and correlates with the cutaneous lupus area and severity index score. Br J Dermatol 2012; 166: 971\u2013975.","DOI":"10.1111\/j.1365-2133.2012.10825.x"},{"key":"168643","doi-asserted-by":"crossref","unstructured":"Billi AC, Ma F, Plazyo O, Gharaee-Kermani M, Wasikowski R, Hile GA, et al. Non-lesional and lesional lupus skin share inflammatory phenotypes that drive activation of CD16+ dendritic cells. Immunology. Preprinted posted online 2021.","DOI":"10.1101\/2021.09.17.460124"},{"key":"168644","doi-asserted-by":"crossref","unstructured":"Hile GA, Werth VP. Understanding the role of type I interferons in cutaneous lupus and dermatomyositis: toward better therapeutics. Arthritis Rheumatol 2025; 77: 1\u201311.","DOI":"10.1002\/art.42983"},{"key":"168645","doi-asserted-by":"crossref","unstructured":"Niewold TB. Interferon alpha as a primary pathogenic factor in human lupus. J Interferon Cytokine Res 2011; 31: 887\u2013892.","DOI":"10.1089\/jir.2011.0071"},{"key":"168646","doi-asserted-by":"crossref","unstructured":"R\u00f6nnblom L, Leonard D. Interferon pathway in SLE: one key to unlocking the mystery of the disease. Lupus Sci Med 2019; 6: e000270.","DOI":"10.1136\/lupus-2018-000270"}],"container-title":["Acta Dermato-Venereologica"],"original-title":[],"link":[{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/46889\/55524","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/46889\/55525","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/46889\/55526","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/46889\/55524","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T14:19:09Z","timestamp":1789654749000},"score":1,"resource":{"primary":{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/view\/46889"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,17]]},"references-count":12,"URL":"https:\/\/doi.org\/10.2340\/actadv.v106.adv-2026-0559","relation":{},"ISSN":["1651-2057","0001-5555"],"issn-type":[{"value":"1651-2057","type":"electronic"},{"value":"0001-5555","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9,17]]}}}